These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38207211)

  • 1. IL-1β promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stem cells.
    Rai S; Zhang Y; Grockowiak E; Kimmerlin Q; Hansen N; Stoll CB; Usart M; Luque Paz D; Hao-Shen H; Zhu Y; Roux J; Bader MS; Dirnhofer S; Farady CJ; Schroeder T; Méndez-Ferrer S; Skoda RC
    Blood Adv; 2024 Mar; 8(5):1234-1249. PubMed ID: 38207211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of Dnmt3a increases self-renewal and resistance to pegIFN-α in JAK2-V617F-positive myeloproliferative neoplasms.
    Usart M; Stetka J; Luque Paz D; Hansen N; Kimmerlin Q; Almeida Fonseca T; Lock M; Kubovcakova L; Karjalainen R; Hao-Shen H; Börsch A; El Taher A; Schulz J; Leroux JC; Dirnhofer S; Skoda RC
    Blood; 2024 Jun; 143(24):2490-2503. PubMed ID: 38493481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F.
    Lundberg P; Takizawa H; Kubovcakova L; Guo G; Hao-Shen H; Dirnhofer S; Orkin SH; Manz MG; Skoda RC
    J Exp Med; 2014 Oct; 211(11):2213-30. PubMed ID: 25288396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK2-V617F and interferon-α induce megakaryocyte-biased stem cells characterized by decreased long-term functionality.
    Rao TN; Hansen N; Stetka J; Luque Paz D; Kalmer M; Hilfiker J; Endele M; Ahmed N; Kubovcakova L; Rybarikova M; Hao-Shen H; Geier F; Beisel C; Dirnhofer S; Schroeder T; Brümmendorf TH; Wolf D; Koschmieder S; Skoda RC
    Blood; 2021 Apr; 137(16):2139-2151. PubMed ID: 33667305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis.
    Shimizu T; Kubovcakova L; Nienhold R; Zmajkovic J; Meyer SC; Hao-Shen H; Geier F; Dirnhofer S; Guglielmelli P; Vannucchi AM; Feenstra JD; Kralovics R; Orkin SH; Skoda RC
    J Exp Med; 2016 Jul; 213(8):1479-96. PubMed ID: 27401344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of interleukin-1β reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm.
    Rai S; Grockowiak E; Hansen N; Luque Paz D; Stoll CB; Hao-Shen H; Mild-Schneider G; Dirnhofer S; Farady CJ; Méndez-Ferrer S; Skoda RC
    Nat Commun; 2022 Sep; 13(1):5346. PubMed ID: 36100613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deletion of Stat3 in hematopoietic cells enhances thrombocytosis and shortens survival in a JAK2-V617F mouse model of MPN.
    Grisouard J; Shimizu T; Duek A; Kubovcakova L; Hao-Shen H; Dirnhofer S; Skoda RC
    Blood; 2015 Mar; 125(13):2131-40. PubMed ID: 25595737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms.
    Arranz L; Sánchez-Aguilera A; Martín-Pérez D; Isern J; Langa X; Tzankov A; Lundberg P; Muntión S; Tzeng YS; Lai DM; Schwaller J; Skoda RC; Méndez-Ferrer S
    Nature; 2014 Aug; 512(7512):78-81. PubMed ID: 25043017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutrophil-specific expression of JAK2-V617F or CALRmut induces distinct inflammatory profiles in myeloproliferative neoplasia.
    Haage TR; Charakopoulos E; Bhuria V; Baldauf CK; Korthals M; Handschuh J; Müller P; Li J; Harit K; Nishanth G; Frey S; Böttcher M; Fischer KD; Dudeck J; Dudeck A; Lipka DB; Schraven B; Green AR; Müller AJ; Mougiakakos D; Fischer T
    J Hematol Oncol; 2024 Jun; 17(1):43. PubMed ID: 38853260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of JAK1/2 inhibition on bone marrow stromal cells of myeloproliferative neoplasm (MPN) patients and healthy individuals.
    Zacharaki D; Ghazanfari R; Li H; Lim HC; Scheding S
    Eur J Haematol; 2018 Jul; 101(1):57-67. PubMed ID: 29645296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAK2
    Lin CH; Kaushansky K; Zhan H
    Blood Cells Mol Dis; 2016 Nov; 62():42-48. PubMed ID: 27865175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression.
    Marty C; Lacout C; Droin N; Le Couédic JP; Ribrag V; Solary E; Vainchenker W; Villeval JL; Plo I
    Leukemia; 2013 Nov; 27(11):2187-95. PubMed ID: 23558526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα.
    Hasan S; Lacout C; Marty C; Cuingnet M; Solary E; Vainchenker W; Villeval JL
    Blood; 2013 Aug; 122(8):1464-77. PubMed ID: 23863895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAK2
    Zhan H; Ma Y; Lin CH; Kaushansky K
    Leukemia; 2016 Dec; 30(12):2332-2341. PubMed ID: 27133820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superior detection of low-allele burden Janus kinase 2 V617F mutation and monitoring clonal evolution in myeloproliferative neoplasms using chip-based digital PCR.
    Lu Y; Lin L; Lin J; Wu B; Cai G; Wang X; Ma X
    Ann Hematol; 2024 Sep; 103(9):3553-3562. PubMed ID: 39043913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAK2V617F-dependent down regulation of SHP-1 expression participates in the selection of myeloproliferative neoplasm cells in the presence of TGF-β.
    Aoun C; Maslah N; Ganesan S; Salomao N; Gendron R; Awan Toor S; Letort G; Gou P; Bonnamy M; Parietti V; Kiladjian JJ; Giraudier S; Cassinat B
    J Cell Mol Med; 2024 Oct; 28(20):e70138. PubMed ID: 39431551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
    Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
    Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hmga2 collaborates with
    Ueda K; Ikeda K; Ikezoe T; Harada-Shirado K; Ogawa K; Hashimoto Y; Sano T; Ohkawara H; Kimura S; Shichishima-Nakamura A; Nakamura Y; Shikama Y; Mori T; Mason PJ; Bessler M; Morishita S; Komatsu N; Shide K; Shimoda K; Koide S; Aoyama K; Oshima M; Iwama A; Takeishi Y
    Blood Adv; 2017 Jun; 1(15):1001-1015. PubMed ID: 29296743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
    Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M
    FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contributions of bone marrow monocytes/macrophages in myeloproliferative neoplasms with JAK2
    Fan W; Cao W; Shi J; Gao F; Wang M; Xu L; Wang F; Li Y; Guo R; Bian Z; Li W; Jiang Z; Ma W
    Ann Hematol; 2023 Jul; 102(7):1745-1759. PubMed ID: 37233774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.